Mark Westerman
Overview
Explore the profile of Mark Westerman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
58
Citations
1843
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Krepuska M, Mayer B, Vitale-Cross L, Myneni V, Boyajian M, Nemeth K, et al.
Sci Rep
. 2024 Feb;
14(1):3986.
PMID: 38368463
Bone marrow stromal cells (BMSCs) have immunomodulatory activities in numerous species and have been used in clinical trials. BMSCs also make antibacterial agents. Since hepcidin is known to have antimicrobial...
2.
Verhaeghe R, George K, Westerman M, Olbina G, McCann D, Parrow N, et al.
Neonatology
. 2020 Aug;
117(4):474-479.
PMID: 32818935
Introduction: The basis for the superior absorption of iron from breast milk compared with infant formulas is unclear. The hormone hepcidin downregulates dietary iron absorption. Hepcidin production increases with increased...
3.
Gutschow P, Han H, Olbina G, Westerman K, Nemeth E, Ganz T, et al.
J Appl Lab Med
. 2020 Jul;
5(5):943-953.
PMID: 32674118
Background: Serum markers currently used as indicators of iron status have clinical limitations. Hepcidin, a key regulator of iron homeostasis, is reduced in iron deficiency (ID) and increased in iron...
4.
Albert C, Haase M, Albert A, Kropf S, Bellomo R, Westphal S, et al.
Ann Lab Med
. 2019 Oct;
40(2):131-141.
PMID: 31650729
Background: The ability of urinary biomarkers to complement established clinical risk prediction models for postoperative adverse kidney events is unclear. We assessed the effect of urinary biomarkers linked to suspected...
5.
Heeney M, Guo D, De Falco L, Campagna D, Olbina G, Kao P, et al.
Blood
. 2018 Jun;
132(4):448-452.
PMID: 29895660
No abstract available.
6.
Panwar B, McCann D, Olbina G, Westerman M, Gutierrez O
BMC Nephrol
. 2018 Feb;
19(1):35.
PMID: 29426300
Background: Anemia is highly prevalent in chronic kidney disease (CKD). Elevated hepcidin concentrations are an important mediator of disordered iron metabolism, a key mechanism underlying anemia of CKD. Vitamin D...
7.
van der Vorm L, Hendriks J, Laarakkers C, Klaver S, Armitage A, Bamberg A, et al.
Clin Chem
. 2016 May;
62(7):993-1001.
PMID: 27173010
Background: Absolute plasma hepcidin concentrations measured by various procedures differ substantially, complicating interpretation of results and rendering reference intervals method dependent. We investigated the degree of equivalence achievable by harmonization...
8.
Li H, Condon F, Kessler D, Nandi V, Rebosa M, Westerman M, et al.
J Clin Apher
. 2016 Feb;
31(6):551-558.
PMID: 26915437
Background: The loss of iron stores and resulting iron deficiency is well documented in whole blood or red blood cell donors. We hypothesized that relative iron deficiency also occurs as...
9.
Brigandi R, Johnson B, Oei C, Westerman M, Olbina G, de Zoysa J, et al.
Am J Kidney Dis
. 2016 Feb;
67(6):861-71.
PMID: 26827289
Background: Anemia associated with chronic kidney disease (CKD) often requires treatment with recombinant human erythropoietin (EPO). Hypoxia-inducible factor-prolyl hydroxylase inhibitors (PHIs) stimulate endogenous EPO synthesis and induce effective erythropoiesis by...
10.
Chen H, Choesang T, Li H, Sun S, Pham P, Bao W, et al.
Haematologica
. 2015 Dec;
101(3):297-308.
PMID: 26635037
Iron overload results in significant morbidity and mortality in β-thalassemic patients. Insufficient hepcidin is implicated in parenchymal iron overload in β-thalassemia and approaches to increase hepcidin have therapeutic potential. We...